Chapter 36: Assessment of the Hematologic System

The hematologic system originates in bone marrow, which continuously produces three major cell lines: red blood cells for oxygen transport and tissue perfusion, white blood cells for immune defense, and platelets for hemostatic control. Understanding hemostasis is central to clinical assessment, as this tightly regulated multistep process maintains the critical balance between clot formation and fibrinolysis, the enzymatic breakdown of clots. Excessive clotting or bleeding both compromise perfusion and organ function. A comprehensive patient history must address medications that alter hemostatic balance, particularly anticoagulants that prevent new thrombus formation and nonsteroidal anti-inflammatory drugs that impair platelet function. Nutritional assessment focuses on vitamin K intake and hepatic function, since the liver synthesizes most vitamin K-dependent clotting factors, making liver disease a significant risk for bleeding disorders. Physical examination techniques include inspection for clinical indicators of impaired perfusion and anemia such as pallor in mucous membranes and palmar creases, and recognition of petechiae as evidence of capillary fragility or thrombocytopenia. A critical safety principle is avoiding palpation of the spleen in suspected hematologic pathology due to risk of splenic rupture if enlargement is present. Diagnostic evaluation distinguishes pharmacologic interventions based on mechanism: anticoagulants prevent clot initiation while fibrinolytic agents actively dissolve existing thrombi. Invasive procedures including bone marrow aspiration and biopsy require meticulous sterile technique, application of sustained pressure for minimum five minutes at venipuncture sites to achieve hemostasis, and activity restriction for forty-eight hours post-procedure to prevent bleeding complications and ensure adequate clot stabilization.